SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

ARVN

Arvinas Inc.
BEARISH
Impact 8/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The severe revenue decline and EPS miss will pressure the stock near-term, but the VEPPANU approval and Rigel out-licensing provide a long-term floor. Watch for HSR clearance on the Rigel deal and upcoming pipeline catalysts (ARV-102 PSP trial initiation, ARV-806 initial data) in 2H 2026. The cash runway into 2H 2028 reduces near-term dilution risk.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.57
T+0 close · May 12, 2026 · via day close
Latest settled
−9.30%
T+60 · $8.68
Vs SPY
−13.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $9.57entry
  2. T+1 · 6mo ago +3.13%α +2.56% · $9.87
  3. T+5 · 6mo ago −8.26%α −8.33% · $8.78
  4. T+20 · 5mo ago −27.06%α −25.34% · $6.98
  5. T+60 · 3mo ago −9.30%α −13.68% · $8.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188.8M) and a GAAP EPS of -$0.90, significantly missing the consensus estimate of -$0.63. The revenue collapse was driven by the removal of two Phase 3 trials from the Pfizer collaboration plan, which had inflated prior-year revenue. While the FDA approval of VEPPANU (first-ever PROTAC) and its out-licensing to Rigel are transformative milestones, the severe revenue decline and EPS miss dominate the near-term narrative.

Key Financial Metrics

EPS
−$0.90
est −$0.63 · -42.9%
Revenue
$15.6M
est $34.8M · -55.2% · -91.7% YoY
Rating
strong miss

Key Facts

  • Q1 2026 revenue of $15.6M vs $188.8M YoY, a 91.7% decline due to changes in Pfizer collaboration cost estimates
  • GAAP EPS of -$0.90 vs consensus -$0.63, a 42.9% miss
  • Cash burn of $67.5M in operations during Q1; cash position $614.9M, sufficient into 2H 2028
  • FDA approval of VEPPANU (vepdegestrant) as first-ever PROTAC therapy for ER+/HER2- breast cancer
  • Out-licensing of VEPPANU to Rigel Pharmaceuticals for exclusive global rights (closing pending HSR review)
  • R&D expenses fell 33.6% YoY to $60.3M, driven by reduced vepdegestrant program costs
  • Pipeline progress: ARV-102 Phase 1 biomarker data, ARV-806 dose escalation completed, ARV-393 combo trial initiated

Financial Impact

Revenue collapsed 91.7% YoY to $15.6M; EPS miss of 42.9% vs consensus; operating cash burn of $67.5M in Q1

revenueepscash burn

Risk Factors

  • Revenue collapse driven by Pfizer collaboration changes may signal further partnership uncertainty
  • VEPPANU commercial success depends on Rigel's execution and market adoption post-approval
  • Pipeline setbacks in ARV-102, ARV-806, or ARV-393 could impair valuation given thin revenue base

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292695

Track record

21 reports on ARVN

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Viewing Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026